Northwest Biotherapeutics reported $4.56M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Agenus USD 35M 32M Mar/2026
AstraZeneca USD 7.56B 1.85B Mar/2026
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Celldex Therapeutics USD 35.73M 6.86M Mar/2026
Eisai JPY 301.65B 16.27B Sep/2025
Infinity Pharmaceuticals USD 17.75M 7.99M Jun/2023
Merck USD 5.33B 9.24B Mar/2026
Northwest Biotherapeutics USD 4.56M 244K Sep/2025
Pfizer USD 1.7B 561M Mar/2026
Plus Therapeutics USD 3.02M 1.23M Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025